APRAMEYA
Aprameya Enginee financials
- Market cap
- ₹221 Cr
- Sector
- Healthcare
- Calls analysed
- 1
Aprameya Enginee Q4 FY25
What went well
- Revenue grew by 108% YoY to INR 136 crores in FY25, driven by a greater share of high-margin turnkey projects.
- EBITDA increased by 267% YoY to INR 25 crores in FY25, with margins improving 795 basis points to 18%.
- PAT rose by 364% YoY to INR 16 crores in FY25, with PAT margin improving from 653 basis points to 12%.
What to watch
- Negative cash flow from operations in the past three years, though management is actively working to reduce debtor days.
- High debtor days (currently 6 months, aiming for 4-5 months) impacting working capital.
What Aprameya Enginee does
Aprameya Engineering, established in 2003, designs, sets up and maintains critical hospital infrastructure — ICUs, NICUs, PICUs, Operation Theatres, Dialysis Centers and Prefabricated Wards — on a turnkey basis for government and private hospitals, including hospital design, equipment procurement, supply, commissioning and installation planning. It also supplies high-value medical and diagnostic equipment to hospitals and medical practitioners as an authorized distributor for manufacturers such as Johnson & Johnson, Philips India, Schiller Healthcare, Alan Electronics Systems, ResMed and Karl Storz Endoscopy. The company is not engaged in any manufacturing activity itself; its turnkey/EPC projects (largely for government medical colleges and hospitals) are complemented by after-sales service and AMC/CAMC maintenance contracts.
Segments
- Healthcare Infrastructure Projects
- Medical Equipment Solutions
- Service & CAMC Solutions
- Dialysis centers delivered (Rajasthan)
- 180+ till date
- States of current operating presence
- Gujarat, Rajasthan, Maharashtra, Delhi
- States targeted for expansion
- Bihar, Daman, Uttarakhand, Assam, Chhattisgarh, Sikkim, Odisha
- Modular OTs under Gujarat PIU order
- 30 (across medical colleges in Surat, Valsad, Junagadh, Rajkot)
- Authorized global equipment-partner manufacturers
- 5+
- Business segments
- 3 (Healthcare Infrastructure Projects, Medical Equipment Solutions, Service & CAMC Solutions)
Guidance record · Q4 FY25
what the last two calls moved 4 tracked 0 delivered 0 missed 4 open- Order Book Execution Timeline open said Q4 FY25 Promised: 5-6 months Q4 FY25: Currently, we are having our order book of around INR60 crores, and that is to be executed within, I think, 5 to 6 months
All 4 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
| Line item | Q2 FY25 | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|---|
| Revenue | 9 | 126 | 42 | 13 |
| EBITDA | -1 | 26 | 11 | -1 |
| Net profit | -2 | 18 | 7 | -2 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −55.8% 1Y
1Y: ₹262.25 on 10 Sept 2025 → ₹116. High ₹352.75 (20 Nov 2025), low ₹103.25 (8 Sept 2026).
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹4 Cr | ₹7 Cr | ₹14 Cr | ₹14 Cr | ₹19 Cr | ₹19 Cr |
| Reserves | ₹0 Cr | ₹7 Cr | ₹6 Cr | ₹9 Cr | ₹52 Cr | ₹50 Cr |
| Borrowings | ₹1 Cr | ₹14 Cr | ₹29 Cr | ₹42 Cr | ₹37 Cr | ₹7 Cr |
| Other liabilities | ₹5 Cr | ₹20 Cr | ₹13 Cr | ₹10 Cr | ₹26 Cr | ₹5 Cr |
| Total liabilities | ₹11 Cr | ₹49 Cr | ₹62 Cr | ₹76 Cr | ₹135 Cr | ₹82 Cr |
| Fixed assets | ₹1 Cr | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹10 Cr | ₹47 Cr | ₹60 Cr | ₹74 Cr | ₹133 Cr | ₹80 Cr |
| Total assets | ₹11 Cr | ₹49 Cr | ₹62 Cr | ₹76 Cr | ₹135 Cr | ₹82 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Mar 2026
Since Mar 2025, promoters added +0.52 pp while FIIs trimmed −0.41 pp. The shareholder count grew 49% to 933.
- Promoters
- 74.0%
- DIIs
- 0.7%
- Public
- 25.2%
Since Mar 2025
- Promoters +0.52 pp
- FIIs −0.41 pp
- Public −0.10 pp
How it drifted, 4 quarters
Over this window the public went from 18.6% to 25.2% — +6.6 pp.
Ownership split by quarter, oldest first. Sep '24: Promoters 73.5%, FIIs 2.5%, DIIs 5.4%, Public 18.6%.Mar '25: Promoters 73.5%, FIIs 0.4%, DIIs 0.7%, Public 25.3%.Sep '25: Promoters 73.5%, DIIs 0.8%, Public 25.7%.Mar '26: Promoters 74.0%, DIIs 0.7%, Public 25.2%.
Who bought this quarter
since Sep 2025
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Saurabh Kishorbhai Bhatt +0.26 pp 36.50% held
- Chetan Mohan Joshi +0.26 pp 36.50% held
The same filing shows 0 holders trimming and 1 off the list — both are in the register beside this.
Who is on the register
Named in the Mar 2026 filing
Every holder of Aprameya Enginee above SEBI's 1% disclosure line, and what changed since Sep 2025.
| Holder | Stake | Change |
|---|---|---|
| Saurabh Kishorbhai Bhatt | 36.50% | +0.26 pp |
| Chetan Mohan Joshi | 36.50% | +0.26 pp |
| Gaurav Jain | 1.21% | unchanged |
| Archana Chetan Joshi | 0.32% | unchanged |
| Pooja Saurabh Bhatt | 0.32% | unchanged |
| Mohan Champalalji Joshi | 0.21% | unchanged |
| Devyaniben Kishorbhai Bhatt | 0.11% | unchanged |
| Kishore Ichhashankar Bhatt | 0.11% | unchanged |
| Pradeep Oza | 0.00% | unchanged |
| Gajanand Trivedi | 0.00% | unchanged |
| Jayshree Trivedi | 0.00% | unchanged |
| Chetan Mohan Joshi Huf | 0.00% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Aprameya Enginee
Guides on how to read this kind of business and the numbers that matter.